FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890873798> ?p ?o ?g. }

• W2890873798 endingPage "867" @default.
• W2890873798 startingPage "857" @default.
• W2890873798 abstract "Abstract Background Acute inflammation, and subsequent release of bacterial products (e.g. LPS), inflammatory cytokines, and stress hormones, is catabolic, and the loss of lean body mass predicts morbidity and mortality. Lipid intermediates may reduce protein loss, but the roles of free fatty acids (FFAs) and ketone bodies during acute inflammation are unclear. Objective We aimed to test whether infusions of 3-hydroxybutyrate (3OHB), FFAs, and saline reduce protein catabolism during exposure to LPS and Acipimox (to restrict and control endogenous lipolysis). Design A total of 10 healthy male subjects were randomly tested 3 times, with: 1) LPS, Acipimox (Olbetam) and saline, 2) LPS, Acipimox, and nonesterified fatty acids (Intralipid), and 3) LPS, Acipimox, and 3OHB, during a 5-h basal period and a 2-h hyperinsulinemic, euglycemic clamp. Labeled phenylalanine, tyrosine, and urea tracers were used to estimate protein kinetics, and muscle biopsies were taken for Western blot analysis of protein metabolic signaling. Results 3OHB infusion increased 3OHB concentrations (P < 0.0005) to 3.5 mM and decreased whole-body phenylalanine-to-tyrosine degradation. Basal and insulin-stimulated net forearm phenylalanine release decreased by >70% (P < 0.005), with both appearance and phenylalanine disappearance being profoundly decreased. Phosphorylation of eukaryotic initiation factor 2α at Ser51 was increased in skeletal muscle, and S6 kinase phosphorylation at Ser235/236 tended (P = 0.074) to be decreased with 3OHB infusion (suggesting inhibition of protein synthesis), whereas no detectable effects were seen on markers of protein breakdown. Lipid infusion did not affect phenylalanine kinetics, and insulin sensitivity was unaffected by interventions. Conclusion During acute inflammation, 3OHB has potent anticatabolic actions in muscle and at the whole-body level; in muscle, reduction of protein breakdown overrides inhibition of synthesis. This trial was registered at clinicaltrials.gov as NCT01752348." @default.
• W2890873798 created "2018-09-27" @default.
• W2890873798 creator A5001772428 @default.
• W2890873798 creator A5022654022 @default.
• W2890873798 creator A5026896800 @default.
• W2890873798 creator A5051841150 @default.
• W2890873798 creator A5064270055 @default.
• W2890873798 creator A5067146363 @default.
• W2890873798 creator A5090850055 @default.
• W2890873798 date "2018-09-18" @default.
• W2890873798 modified "2023-10-15" @default.
• W2890873798 title "Effects of 3-hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling during LPS-induced inflammation in humans: anticatabolic impact of ketone bodies" @default.
• W2890873798 cites W1501737793 @default.
• W2890873798 cites W1880070597 @default.
• W2890873798 cites W1930095565 @default.
• W2890873798 cites W1940869776 @default.
• W2890873798 cites W1962137879 @default.
• W2890873798 cites W1968201317 @default.
• W2890873798 cites W1969914910 @default.
• W2890873798 cites W1971004951 @default.
• W2890873798 cites W1980220650 @default.
• W2890873798 cites W1982347002 @default.
• W2890873798 cites W1986705989 @default.
• W2890873798 cites W1991680312 @default.
• W2890873798 cites W1992523552 @default.
• W2890873798 cites W1995705381 @default.
• W2890873798 cites W2013644966 @default.
• W2890873798 cites W2015173256 @default.
• W2890873798 cites W2019605946 @default.
• W2890873798 cites W2021176399 @default.
• W2890873798 cites W2026826434 @default.
• W2890873798 cites W2029296519 @default.
• W2890873798 cites W2030786330 @default.
• W2890873798 cites W2041910805 @default.
• W2890873798 cites W2051387018 @default.
• W2890873798 cites W2051624153 @default.
• W2890873798 cites W2056993100 @default.
• W2890873798 cites W2057175445 @default.
• W2890873798 cites W2057321871 @default.
• W2890873798 cites W2058039595 @default.
• W2890873798 cites W2077600824 @default.
• W2890873798 cites W2079577855 @default.
• W2890873798 cites W2081262717 @default.
• W2890873798 cites W2081434876 @default.
• W2890873798 cites W2084436915 @default.
• W2890873798 cites W2086921193 @default.
• W2890873798 cites W2122547285 @default.
• W2890873798 cites W2124232607 @default.
• W2890873798 cites W2126365814 @default.
• W2890873798 cites W2129398780 @default.
• W2890873798 cites W2129649014 @default.
• W2890873798 cites W2133281251 @default.
• W2890873798 cites W2137225377 @default.
• W2890873798 cites W2140803964 @default.
• W2890873798 cites W2141511467 @default.
• W2890873798 cites W2142813361 @default.
• W2890873798 cites W2153817859 @default.
• W2890873798 cites W2158787135 @default.
• W2890873798 cites W2159445530 @default.
• W2890873798 cites W2400197929 @default.
• W2890873798 cites W2464771298 @default.
• W2890873798 cites W2508534437 @default.
• W2890873798 cites W2518959324 @default.
• W2890873798 cites W2519646341 @default.
• W2890873798 cites W2587156779 @default.
• W2890873798 cites W2593816418 @default.
• W2890873798 cites W2594282927 @default.
• W2890873798 cites W2752326209 @default.
• W2890873798 doi "https://doi.org/10.1093/ajcn/nqy170" @default.
• W2890873798 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30239561" @default.
• W2890873798 hasPublicationYear "2018" @default.
• W2890873798 type Work @default.
• W2890873798 sameAs 2890873798 @default.
• W2890873798 citedByCount "76" @default.
• W2890873798 countsByYear W28908737982018 @default.
• W2890873798 countsByYear W28908737982019 @default.
• W2890873798 countsByYear W28908737982020 @default.
• W2890873798 countsByYear W28908737982021 @default.
• W2890873798 countsByYear W28908737982022 @default.
• W2890873798 countsByYear W28908737982023 @default.
• W2890873798 crossrefType "journal-article" @default.
• W2890873798 hasAuthorship W2890873798A5001772428 @default.
• W2890873798 hasAuthorship W2890873798A5022654022 @default.
• W2890873798 hasAuthorship W2890873798A5026896800 @default.
• W2890873798 hasAuthorship W2890873798A5051841150 @default.
• W2890873798 hasAuthorship W2890873798A5064270055 @default.
• W2890873798 hasAuthorship W2890873798A5067146363 @default.
• W2890873798 hasAuthorship W2890873798A5090850055 @default.
• W2890873798 hasBestOaLocation W28908737981 @default.
• W2890873798 hasConcept C126322002 @default.
• W2890873798 hasConcept C134018914 @default.
• W2890873798 hasConcept C140985366 @default.
• W2890873798 hasConcept C171089720 @default.
• W2890873798 hasConcept C185592680 @default.
• W2890873798 hasConcept C197683979 @default.
• W2890873798 hasConcept C2776165026 @default.
• W2890873798 hasConcept C2776914184 @default.
• W2890873798 hasConcept C2777431362 @default.

• next